1 minute treatment update

Treatment pearls in your chosen speciality or topic, as they are published, updated every 48 hours.
Last updated on 2024/05/23.





Ital J Dermatol Venerol 23 May. 2024.
Successful therapy of refractory cutaneous morphea with tofacitinib.

Sorry! No treatment pearl could be fetched.

 Pubmed Scholar sci-hub

Ital J Dermatol Venerol 23 May. 2024.
Pediatric Stevens-Johnson syndrome/toxic epidermal necrolysis overlap; time to draw up treatment guidelines?

Sorry! No treatment pearl could be fetched.

 Pubmed Scholar sci-hub

Int J Dermatol 23 May. 2024.
Demographics and treatment trends in the largest cohort of patients with Down syndrome and hidradenitis suppurativa.

Sorry! No treatment pearl could be fetched.

 Pubmed Scholar sci-hub

Front Immunol . 2024.
Troxerutin suppress inflammation response and oxidative stress in jellyfish dermatitis by activating Nrf2/HO-1 signaling pathway.

TRX inhibits the major signaling pathway responsible for inducing inflammatory and oxidative damage of jellyfish dermatitis, offering a novel therapy in clinical applications.

 Pubmed Scholar sci-hub

J Clin Aesthet Dermatol May. 2024.
Putting the Formulation Back in Foam: Optimizing Seborrheic Dermatitis Treatment Across Diverse Hair Types.

We conducted a comprehensive assessment of beauty industry standards, confirming the foam formulation's alignment with industry guidelines and exclusion of potentially harmful ingredients. In addition, consultation with an expert dermatologist panel yielded a strong endorsement, underscoring a high level of confidence in prescribing the foam across diverse hair and skin types

 Pubmed Scholar sci-hub

Clin Cosmet Investig Dermatol . 2024.
Congenital Triangular Alopecia: A Case of Effective Response with 5% Topical Minoxidil in a Male Adolescent.

After eight months of treatment, the affected area was fully covered with dense terminal hairs. The patient did not report any adverse reactions/side effects

 Pubmed Scholar sci-hub

JAAD Case Rep Jun. 2024.
Anifrolumab for the treatment of refractory chilblain lupus erythematosus.

Sorry! No treatment pearl could be fetched.

 Pubmed Scholar sci-hub

Clin Exp Dermatol 23 May. 2024.
From Skin Check to Suturing: Efficacy of a Sequential Dermatology Simulation for Medical Students.

Sorry! No treatment pearl could be fetched.

 Pubmed Scholar sci-hub

Curr Pharm Des 22 May. 2024.
Targeted Biologic Therapies in Chronic Prurigo: The Evolving Landscape of Chronic Prurigo Treatment.

Sorry! No treatment pearl could be fetched.

 Pubmed Scholar sci-hub

J Dtsch Dermatol Ges 22 May. 2024.
SDRIFE and bullous reaction after treatment with enfortumab vedotin plus pembrolizumab: Case series.

Sorry! No treatment pearl could be fetched.

 Pubmed Scholar sci-hub

Dermatol Ther (Heidelb) 22 May. 2024.
Baricitinib Improvement Across Regions in Atopic Dermatitis Patients with Baseline Body Surface Area up to 40% and Severe Itch.

BARI itch-dominant patients exhibit AD involvement across all body regions and considerable sign severity, especially erythema. In response to BARI 4 mg, EASI quickly improved across regions, substantially more so in this subtype than in the ITT population.

 Pubmed Scholar sci-hub

Psychooncology May. 2024.
How do mindfulness-based interventions promote coping and self-efficacy in patients with cancer: A systematic review of qualitative and quantitative data.

The reviewed studies suggest that MBI can promote coping and enhance the perceived self-efficacy of patients with cancer. In the future, more research investigating the different aspects of coping and the potentially moderating role of self-efficacy could provide further insights with respect to how coping and self-efficacy related to MBI.

 Pubmed Scholar sci-hub

Ann Rheum Dis 22 May. 2024.
Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX.

This study shows the benefit of JAKi and IL-6 inhibitors, whereas other therapies have lower efficacy. These results need to be confirmed in prospective trials.

 Pubmed Scholar sci-hub

J Dermatolog Treat Dec. 2024.
Effectiveness and safety of risankizumab in VEry severe plaque psoriasis: a real-life retrospective study (VESPA-Study).

Risankizumab showed to be effective and safe in patients affected by very severe forms of psoriasis with the involvement of difficult-to-treat areas.

 Pubmed Scholar sci-hub

J Am Acad Dermatol 20 May. 2024.
Response to Bass et al.'s "Significant discordance in DermTech test results when paired with histopathology: Caveat emptor.".

Sorry! No treatment pearl could be fetched.

 Pubmed Scholar sci-hub

Ann Dermatol Venereol 21 May. 2024.
Barriers and suggestions for improving the implementation of guidelines in the systemic treatment of moderate to severe psoriasis: A literature review.

Various barriers to implementation of recommendations exist, such as economic barriers, lack of dermatologic orientation towards, lack of knowledge of recommendations by other specialists, lack of applicability, and country- and practice-specific features (e.g., different benefit/risk ratios, different reimbursement rates and conditions). This review can help the everyday practitioner to better understand these barriers, which will have a direct impact on improving the quality of life of psoriasis patients.

 Pubmed Scholar sci-hub

Int Immunopharmacol 21 May. 2024.
Identification of an exosomal miRNA-mRNA regulatory network contributing to methotrexate efficacy.

This pilot investigation found that miR-199a-5p, miR-195-5p, miR-196a-5p, and miR-1246 might be prospective biomarkers to predict the efficacy of MTX, and that miR-191-5p and miR-21-5p were correlated with psoriasis severity. Five of them previously reported to be involved in MAPK signaling pathway, indicating a potential role of MTX in delaying the progression of psoriatic inflammation.

 Pubmed Scholar sci-hub

J Clin Oncol 22 May. 2024.
Vulvar Squamous Cell Carcinoma Guidelines May Benefit From Consideration of Tissue-Sparing Techniques as Treatment Options.

Sorry! No treatment pearl could be fetched.

 Pubmed Scholar sci-hub

Phytother Res 22 May. 2024.
Taraxerone exerts antipulmonary fibrosis effect through Smad signaling pathway and antioxidant stress response in a Sirtuin1-dependent manner.

In vivo validation confirms taraxerone's SIRT1-mediated antifibrotic effectiveness. This suggests that targeting SIRT1-mediated inhibition of myofibroblast differentiation could be a key strategy in taraxerone-based therapy for pulmonary fibrosis

 Pubmed Scholar sci-hub

Skin Res Technol May. 2024.
Comparative efficacy and safety of the treatment by Omalizumab for chronic idiopathic urticaria in the general population: A systematic review and network meta-analysis.

300 mg of omalizumab was the optimum dosage to treat CIU patients, with a 150 mg dose also exhibiting good efficacy. Further studies are required to explore the efficacy and safety of different doses of omalizumab in the treatment of CIU patients.

 Pubmed Scholar sci-hub